832-497-2220 [email protected]

News and Blog

»News and Blog

Exclusive Interview | Interview of Senior Executives at Kintor Pharmaceutical

In the 11 years from its debut in 2009 to its IPO on the Hong Kong Stock Exchange in 2020, Kintor Pharmaceutical has had 5 clinical-stage products under development and carried out multiple phase I-III clinical trials across three continents covering a broad spectrum of diseases. The drug candidates include second-generation androgen receptor (AR) antagonist Proxalutamide, AR antagonist Pyrilutamide, fully human monoclonal antibody GT90001 (ALK-1), and others. The milestones that Kintor has achieved are due to team members’ perseverance, insight into market demand and the embracing of team diversity.

Today’s interviewees are from the Kintor executive team. One was an investment bank elite and the other is a doctor who returned to China after working in the US.

Could NLRP3 be the next magic target: the exciting competition between startups and MNCs

As a target of extensive research, NLRP3 is the culprit behind a long list of inflammation-related diseases including diabetes, gout, Alzheimer’s disease, NASH, inflammatory bowel disease, and atherosclerosis.

However, NLRP3 does not have a clear protein structure and, as shown above, involves many diseases. This inevitably makes it a challenge for pharmaceutical companies to start addressing it. Since its discovery in the early 21st century, so far only five NLRP3 drug candidates have entered the clinical stage, reflecting the difficulty of development.

In Hurun’s 2020 Top 500 Chinese Private Enterprises, Hengrui and Mindray Lead the Healthcare Category

Recently, the Hurun Research Institute released their list of “Hurun’s 2020 Top Chinese 500 Private Enterprises”, ranked according to the companies’ market value or valuation. The market value of listed companies is calculated based on closing prices on October 15, 2020, and the valuation of non-listed companies is estimated with reference to listed companies in the same industry. This is the second time that the Hurun Research Institute has released a list of China’s top 500 privat

Top-tier Chinese Pharmaceutical company profile: Simcere Pharmaceutical Group

Simcere is a research and development driven Chinese pharmaceutical company committed to bringing high quality, effective therapies to patients by combining in-house R&D with partnerships. Simcere focuses its efforts on the therapeutic areas of oncology, neurology, inflammation/immunology, cardiovascular and infectious diseases.
The company has over 50 products on the market with three R&D centers, four GMP facilities, and three overseas branches located in the US and Europe. Simcere has achieved a 30% compound annual growth rate in four consecutive years.

GeneScience and Foresee reach an agreement, filling a gap in the Chinese market for GnRH therapies

Endocrine therapy is a first-line therapy for prostate cancer, with gonadotropin-releasing hormones (GnRH) occupying a strong position. Although the incidence of prostate cancer in China is much lower than that in the United States, with life expectancy on the rise the incidence of prostate cancer is increasing as well. Prostate cancer is the most common non-skin cancer and the second leading cause of cancer deaths in men in the United States. According to statistics from the National Cancer Institute, there were more than 170,000 newly diagnosed prostate cancer patients in 2019, and about 30,000 died of prostate cancer.

Industry Research | CGRP Treatments Compete on the Migraine Market

Migraine is a common neurological disease, which can be chronic. According to the Migraine Research Foundation, symptoms include a severe throbbing recurring pain, usually on one side of the head and at least one of the following: “visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face.” Attacks tend to last between 4 and 72 hours. About 15% of the world’s population are affected by migraine, or around 1 billion people. In the United States and China, 39 million and 13 million people suffer from migraine, respectively. Furthermore, migraine disproportionately affects women. According to the WHO’s Global Burden of Disease Study published in 2010, the number of women who suffer from migraine is about three times that of men.